8ZD Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule oncology therapies in Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Abbisko Cayman Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.49 |
| 52 Week High | HK$0.62 |
| 52 Week Low | HK$0.24 |
| Beta | 1.32 |
| 11 Month Change | 5.65% |
| 3 Month Change | 53.80% |
| 1 Year Change | 20.90% |
| 33 Year Change | -55.41% |
| 5 Year Change | n/a |
| Change since IPO | -60.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8ZD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | 0.2% |
| 1Y | 20.9% | -17.2% | 8.5% |
Return vs Industry: 8ZD exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 8ZD exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 8ZD volatility | |
|---|---|
| 8ZD Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 8ZD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8ZD's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 275 | Yao-Chang Xu | www.abbisko.com |
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule oncology therapies in Mainland China. The company’s product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services.
Abbisko Cayman Limited Fundamentals Summary
| 8ZD fundamental statistics | |
|---|---|
| Market cap | €322.42m |
| Earnings (TTM) | -€2.15m |
| Revenue (TTM) | €65.91m |
4.9x
P/S Ratio-150.2x
P/E RatioIs 8ZD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8ZD income statement (TTM) | |
|---|---|
| Revenue | CN¥497.27m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥497.27m |
| Other Expenses | CN¥513.47m |
| Earnings | -CN¥16.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.026 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3.26% |
| Debt/Equity Ratio | 0% |
How did 8ZD perform over the long term?
See historical performance and comparison